CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Group A: oropharygeal spray and immunostimulantWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1014 Group D:Placebo oropharyngeal spray + Placebo taken PO Wiki 1.00
drug1013 Group C:Active principle oropharyngeal spray + Placebo taken PO Wiki 1.00
drug1012 Group B: Placebo oropharyngeal spray + Active principle immunostimulant Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Scheme of Primary Prevention of Infection by COVID-19, in Health Providers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

Introduction: The SARS Co-2 contagious rate is high (Ro: 2.0-3.0). The infection is aggressive with high pathogenicity. Global confinement impacts all social and economic fields of human activity. Clinical behavior exceeds the capabilities of public health care. With the initial information on the pandemic, it is estimated that 20% of health personnel in direct contact with patients can acquire the disease, despite preventive self-care. The molecular relationship of COVID-19 with the subject's ACE2 protein encourages the virus to enter the host cell, and initiates replication and the immune response, causing an imbalance generating an immunological storm of cytokines, with serious damage to the host. Objective: It is proposed to supply a combined scheme of two compounds by oropharyngeal spray that capture the virus before entering the target cell and orally administer immunomodulatory compounds that regulate the inflammatory response released by the virus, in order to improve the antiviral response. Methodology: A controlled, parallel design, triple blind, phase II clinical trial will be conducted with four study groups to compare the active compounds (oropharyngeal spray and capsule) with placebo. Discussion: With the application of the combined scheme of two compounds, a 75% reduction in infection is expected in health providers in direct contact with COVID patients.

NCT04420260 COVID Dietary Supplement: Group A: oropharygeal spray and immunostimulant Dietary Supplement: Group B: Placebo oropharyngeal spray + Active principle immunostimulant Dietary Supplement: Group C:Active principle oropharyngeal spray + Placebo taken PO Dietary Supplement: Group D:Placebo oropharyngeal spray + Placebo taken PO
MeSH:Infection

Primary Outcomes

Description: Seroconversion of IgM for COVID-19. Result of positive IgM antibodies: A previously scheduled closure visit will be conducted, the trial product will be interrupted if a case is classified as severe-critical, and clinical follow up will be continued as planned. As protocols by the Health Ministry dictate, cases will be confirmed with a PCR-RT test, for the diagnosis of COVID-19. The result of the test will be requested to document the outcome.

Measure: Seroconversion of IgM for COVID-19.

Time: 1 month

Secondary Outcomes

Description: seroconversion of IgG

Measure: Seroconversion of IgG for COVID-19.

Time: through study completion, 45 days


No related HPO nodes (Using clinical trials)